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Towards a vaccine for African swine fever 
• Caused by a large double stranded DNA 
virus.
• Between 150-167 genes, 22 genotypes 
based on the p72 sequence.
• Belongs to the family Asfaviridae, nearest 
relatives are the poxviruses.
• There is a wildlife reservoir : warthogs, 
bush pigs. Soft ticks are involved in 
transmission.
African swine fever
• ASF is now a huge problem in Eastern 
Europe, Russia, China, Asia, and Africa.
• ASF is present in about 26 countries in 
Africa. Multiple genotypes are present.
• ASF is a major problem for potential pig 
farmers, who are discouraged from 
entering the pig business due to ASF.
African swine fever
The  architecture of the virus
Wang et al. 2019
Neighbor-Joining tree depicting the p72 gene relationships 
and geographical distribution of the major ASFV genotypes
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Engineering of African Swine Fever Virus 
for Production of Live Attenuated Vaccine 
Candidates 
Engineering of African Swine Fever Virus for 
Production of Live Attenuated Vaccine Candidates 
• Establishment of vaccine platforms for making attenuated 
African swine fever vaccine candidates
• Gene modification by CRISPR-Cas.
• Gene modification by using a synthetic approach – reverse genetics system
• International Livestock Research Institute, J. Craig Venter Institute and 
Friedrich Loeffler Institute.
• The virus
• Genotype IX isolated from an outbreak area 
between Uganda and Kenya. Genomic 
sequence available.
• Viruses from current outbreak areas in the 
region (Kenya, Uganda, (Tanzania)) have been 
sequenced at ILRI. All are genotype IX and X, 
and genomes are almost identical to the one 
we have. Genotype IX and X have been 
detected in outbreaks in Congo.
Virus backbone for modification of ASFV 
Gallardo C et al. A.J. Biotech 2011 
Onzere C. et al. Virus Genes 2018
CRISPR approaches for gene modification 
CRISPR-modification pathway (NHEJ) 
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Reflections on the NHEJ pathway
• Bias towards in-frame indels using NHEJ, one guide RNA approach.
• Difficulties in cloning due to lack of marker for modification.
Mitigation:
• Use HDR approach 
NHEJ pathway 
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GFP plasmid pGFPΔA238L for integration of GFP 
in the ASF genome 
17th Oct 2019
pGFPΔA238L, synthesised by GenScript
circular
linear
Infection /transfection experiments in WSL– Cas cell line
Kenya 1033 (WT) + plasmid
Kenya 1033 (WT) + amplicon
Kenya 1033 (∆CD2v) + plasmid
Kenya 1033 (∆CD2v) + amplicon
Microscopy after transfection of pGFPΔA238L 
in Kenya1033-ΔCD2v-DsRed
Super-imposed images
DsRed eGFP
Two
PCR confirmation of GFP genome integration
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Amplicon sizes:
F1R1 (5′)   =   1488 bp
F1R2  =   3740 bp (KO),  
F1R2 =   3337 bp (wt),   
F2R2 (3′)   =   1681 bp
Expected band sizes for both amplicon and plasmid 
transfections in Kenya1033 & Kenya1033-ΔCD2v 
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PCR to check integration of the plasmid/amplicon into the virus genome
F1 R1 F2 R2
Viruses produced by homology directed 
repair (CRISPR)
Backbones 
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Ready for animal experiments
Towards a subunit vaccine for African 
swine fever
Toward a subunit vaccine
• Identification of antigens for use in a subunit vaccine
• Screening of peptide library in ELISpot
• Production of recombinant viral vectors
• Adenovirus/MVA prime-boost
• Testing of pools of viral vectors in pigs for protection
Adenovirus Vaccinia
Immunisation using attenuated ASF virus 
ASF1033 ΔCD2v
• 10 European breed animals
• 10 local breed animals
Clinical scoring/temperature after immunization 
using  attenuated ASF virus ASF1033ΔCD2v
CD2v knockout
• The virus is attenuated.
• 80-90% of pigs survives 103 HAD.
• Clearly, another mutation is needed.
• We are soon testing if pigs immunized 
with ASF1033ΔCD2v are protected 
against wild-type.
Cellular immune responses after immunization 
using attenuated ASFΔCD2v
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Antibody responses in pigs after 
immunization with attenuated ASFΔCD2v
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Antibody responses in pigs after 
immunization with attenuated ASFΔCD2v
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Recognition by PBMC of overlapping peptides 
spanning the entire proteome
immunization with attenuated ASFΔCD2v
• 217 gene pools in all
• 42 pools recognized in all 3 
screenings.
• 62 pools not recognized
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Peptide pools recognized in ELISpot using full 
proteome library 
immunization with attenuated ASFΔCD2v
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Production of viral vectors with ASF genes
• Ten genes from the peptide 
screen were selected
• Each of the 10 genes 
produced in both 
adenovirus (HuAd5) and 
Modified Vaccinia virus 
Ankara (MVA).
• Next, to test pools in the 
animal model
Virus batch for challenge experiments
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Establishment of minimal lethal challenging dose
HAD-titer: 102, 103, 104, 105
5 animals per group
Scoring system: King et al.
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